Arginine dependence of tumor cells: Targeting a chink in cancer's armor

Oncogene

Volumn 35, Issue 38, 2016, Pages 4957-4972

  Patil, M D ^a   Bhaumik, J ^a   Babykutty, S ^b   Banerjee, U C ^a   Fukumura, D ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGININE; ARGININE DECARBOXYLASE; ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; MACROGOL; NITRIC OXIDE SYNTHASE; ORNITHINE CARBAMOYLTRANSFERASE; ARGINASE; HYDROLASE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME MODIFICATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TUMOR CELL; TUMOR RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROLASES; NEOPLASMS; ORNITHINE CARBAMOYLTRANSFERASE; SIGNAL TRANSDUCTION;

EID: 84964282787     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.37     Document Type: Review

References (215)

1. Wu G. Functional amino acids in nutrition and health. Amino Acids 2013; 45: 407-411.
2. Loreni F, Mancino M, Biffo S. Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogene 2014; 33: 2145-2156.
3. Proud CG. Control of the translational machinery by amino acids. Am J Clin Nutr 2014; 99: 231s-236s.
4. Luo J-Q, Chen D-W, Yu B. Upregulation of amino acid transporter expression induced by l-leucine availability in L6 myotubes is associated with ATF4 signaling through mTORC1-dependent mechanism. Nutrition 2013; 29: 284-290.
5. Palii SS, Kays CE, Deval C, Bruhat A, Fafournoux P, Kilberg MS. Specificity of amino acid regulated gene expression: analysis of genes subjected to either complete or single amino acid deprivation. Amino Acids 2009; 37: 79-88.
6. Qie S, Liang D, Yin C, Gu W, Meng M, Wang C et al. Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming. Cell Cycle 2012; 11: 3679-3690.
7. Agrawal V, Alpini SEJ, Stone EM, Frenkel EP, Frankel AE. Targeting methionine auxotrophy in cancer: discovery and exploration. Expert Opin Biol Ther 2012; 12: 53-61.
8. Wu G, Wu Z, Dai Z, Yang Y, Wang W, Liu C et al. Dietary requirements of ''nutritionally non-essential amino acids'' by animals and humans. Amino Acids 2013; 44: 1107-1113.
9. Fu YM, Yu Z-X, Li Y-Q, Ge X, Sanchez PJ, Fu X et al. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutr Cancer 2003; 45: 60-73.
10. Icard P, Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta Rev Cancer 2012; 1826: 423-433.
11. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Disc 2012; 2: 881-898.
12. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011; 14: 443-451.
13. Ferreira LMR, Hebrant A, Dumont JE. Metabolic reprogramming of the tumor. Oncogene 2012; 31: 3999-4011.
14. Yamamoto T, Takano N, Ishiwata K, Ohmura M, Nagahata Y, Matsuura T et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat Commun 2014; 5: 3480.
15. Matthew G, Heiden V. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Disc 2011; 10: 671-684.
16. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
17. Gelb T, Pshenichkin S, Rodriguez OC, Hathaway HA, Grajkowska E, DiRaddo JO et al. Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas. Oncogene 2015; 34: 2711-2720.
18. Cetinbas N, Daugaard M, Mullen AR, Hajee S, Rotblat B, Lopez A et al. Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction. Oncogene 2015; 34: 4005-4010.
19. Graham ML. Pegaspargase:a review of clinical studies. Adv Drug Deliv Rev 2003; 55: 1293-1302.
20. Durden DL, Distasio JA. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase-free asparaginase from Vibrio succinogenes on specific cell-mediated cytotoxicity. Int J cancer 1981; 27: 59-65.
21. Dodd KM, Tee AR. Leucine and mTORC1: a complex relationship. Am J Physiol Endocrinol Metab 2012; 302: E1329-E1342.
22. Takano N, Sarfraz Y, Gilkes DM, Chaturvedi P, Xiang L, Suematsu M et al. Mol Cancer Res 2014; 12: 1398-1406.
23. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Rhoads JM et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009; 37: 153-168.
24. Appleton J. Arginine: clinical potential of a semi-essential amino acid. Altern Med Rev 2002; 7: 512-522.
25. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE et al. Negative argininosuccinate synthetase expression in melanoma tumors may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 2012; 106: 1481-1485.
26. Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 2012; 3: e342.
27. Wheatley DN. Controlling cancer by restricting arginine availability-Arginine catabolizing enzymes as anticancer agents. Anti-Cancer Drugs 2004; 15: 825-833.
28. García-Navas R, Munder M, Mollinedo F. Depletion of L-Arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes. Autophagy 2012; 8: 1557-1576.
29. Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E. The role of arginine and the modified arginine deiminase enzyme ADI-PEG in cancer therapy with special emphasis on phase I/II clinical trials. Expert Opin Inv Drug 2014; 23: 1517-1529.
30. Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med Sci Monit 2002; 8: BR248-BR253.
31. Qui F, Huang J, Sui M. Targeting arginine metabolism pathway to treat argininedependent cancers. Cancer Lett 2015; 364: 1-7.
32. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: Opportunities and challenges. Cancer Res Treat 2013; 45: 251-262.
33. Noh EJ, Kang SW, Shin YJ, Choi SH, Kim CG, Park IS et al. Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int J Cancer 2004; 112: 502-508.
34. Stasyk OV, Boretsky YR, Gonchar MV, Sibirny AA. Recombinant argininedegrading enzymes in metabolic anticancer therapy and bioanalytics. Cell Biol Int 2015; 39: 246-252.
35. Feun LG, Kuo MT, Savaraj N. Arginine deprivation in cancer therapy. Curr Opin Clin Nutr 2015; 18: 78-82.
36. Shirai H, Blundell TL, Mizuguchi K. A novel superfamily of enzymes that catalyse the modification of guanidine groups. Trends Biochem Sci 2001; 26: 465-468.
37. Huang H-Y, Wu H-Y, Wang Y-H, Wang J-W, Fang F-M, Tsai J-W et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res 2013; 19: 2861-2872.
38. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 2010; 10: 405-412.
39. Kelly MP, Jungbluth AA, Wu B-W, Bomalaski J, Old LJ, Ritter G. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 2012; 106: 324-332.
40. Manca A, Sini MC, Izzo F, Ascierto P, Tatangelo F, Botti G et al. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep 2011; 25: 1495-1502.
41. Jungbluth AA, Tassello J, Frosina D, Hanson N, Ritter G, Wu B-W et al. Expression pattern of argininosuccinate-synthetase (ASS) in normal and tumor tissue as a marker for susceptibility to arginine-deiminase (ADI) therapy. Mod Pathol 2010; 23: 387 A.
42. Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget 2015; 6: 6295-6309.
43. Miyazaki K, Takaku H, Umeda M, Fujita T, Huang W, Kimura T et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res 1990; 50: 4522-4527.
44. Sugimura K, Ohno T, Kusuyama T, Azuma I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res 1992; 2: 191-196.
45. Takaku H, Misawa S, Hayashi H, Miyazaki K. Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini. Jpn J Cancer Res 1993; 84: 1195-1200.
46. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Poly (ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002; 80: 259-271.
47. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002; 62: 5443-5450.
48. Zhang L, Liu M, Jamil S, Han R, Xu G, Ni Y. PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida. Cancer Lett 2015; 357: 346-354.
49. Ni Y, Schwaneberg U, Sun ZH. Arginine deiminase, a potential anti-tumor drug. Cancer Lett 2008; 261: 1-11.
50. Yoon J, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB. Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 2013; 5: 11-19.
51. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010; 28: 2220-2226.
52. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005; 23: 7660-7668.
53. Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 2010; 9: 535-544.
54. Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 2013; 4: e458.
55. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009; 125: 1454-1463.
56. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006; 12: 7126-7131.
57. Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, Agron S et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature 2015; 527: 379-383.
58. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 2006; 15: 815-822.
59. Bobak YP, Vynnytska BO, Kurlishchuk YV, Sibirny AA, Stasyk OV. Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. Cell Biol Int 2010; 34: 1085-1089.
60. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1a/Sp4. Mol Cancer Ther 2009; 8: 3223-3233.
61. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res 2012; 72: 2622-2633.
62. Long Y, Tsai W-B, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG et al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence and glutamine addiction. Mol Cancer Ther 2013; 12: 2581-2590.
63. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008; 14: 1049-1057.
64. Szlosarek PW, Luong P, Phillips MM, Baccarini M, Ellis S, Szyszko T et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 2013; 31: e111-e113.
65. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010; 103: 954-960.
66. You M, Savaraj N, Wangpaichitr M, Wu C, Kuo TM, Varona-Santos J et al. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun 2010; 394: 760-766.
67. Feun LG, Wu G, Clark M, Bombalaski J, Holtsberg F, Wangpaijit M et al. Mechanism of anti-tumor effect of arginine deiminase-polyethylene (ADI-PEG20) and the possible mechanism of resistance in melanoma. Proc Am Assoc Cancer Res 2004; 45: 4565.
68. Wangpaichitr M, Wu C, Bigford G, Theodoropoulos G, You M, Li YY et al. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. Anticancer Res 2014; 34: 6991-7000.
69. You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C et al. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem 2013; 374: 181-190.
70. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009; 69: 700-708.
71. Kim RH, Bold RJ, Kung HJ. ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer. Autophagy 2009; 5: 567-568.
72. Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C et al. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights 2007; 2: 119-128.
73. Gong H, Zölzer F, Recklinghausen G, Havers W, Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 2000; 14: 826-829.
74. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008; 123: 1950-1955.
75. Surova O, Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene 2013; 32: 3789-3797.
76. Changou CA, Chen Y-R, Xing L, Yen Y, Chuang FYS, Cheng RH et al. Arginine starvation-Associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. Proc Natl Acad Sci USA 2014; 111: 14147-14152.
77. Kung H-J, Changou CA, Li C-F, Ann DK. Chromatophagy: autophagy goes nuclear and captures broken chromatin during arginine-starvation. Autophagy 2015; 11: 419-421.
78. Gong H, Zölzer F, Recklinghausen GV, Rössler J, Breit S, Havers W et al. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 1999; 261: 10-14.
79. Lorenzo HK, Susin SA. Mitochondrial effectors in caspase-independent cell death. FEBS Lett 2004; 557: 14-20.
80. Polster BM. AIF, reactive oxygen species, and neurodegeneration: a ''complex'' problem. Neurochem Int 2013; 62: 695-702.
81. Norberg E, Orrenius S, Zhivotovsky B. Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). Biochem Biophys Res Commun 2010; 396: 95-100.
82. Zhu C, Wang X, Deinum J, Huang Z, Gao J, Modjtahedi N et al. Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med 2007; 204: 1741-1748.
83. Pradelli LA, Bénéteau M, Ricci J-E. Mitochondrial control of caspase-dependent and-independent cell death. Cell Mol Life Sci 2010; 67: 1589-1597.
84. Ulukaya E, Acilan C, Yilmaz Y. Apoptosis: why and how does it occur in biology? Cell Biochem Funct 2011; 29: 468-480.
85. Shen LJ, Beloussow K, Shen WC. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 2006; 231: 30-35.
86. Mandal S, Mandal A, Johansson HE, Orjalo AV, Park MH. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc Natl Acad Sci USA 2013; 110: 2169-2174.
87. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4: 781-792.
88. Ohmura M, Hishiki T, Yamamoto T, Nakanishi T, Kubo A, Tsuchihashi K et al. Impacts of CD44 knockdown in cancer cells on tumor and host metabolic systems revealed by quantitative imaging mass spectrometry. Nitric Oxide 2015; 46: 102-113.
89. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
90. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29: 3-9.
91. Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang F et al. Tumor cell-mediated neovascularisation and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta Rev Cancer 2013; 1836: 273-286.
92. Stapor P, Wang X, Goveia J, Moens S, Carmeliet P. Angiogenesis revisited-role and therapeutic potential of targeting endothelial metabolism. J Cell Sci 2014; 127: 4331-4341.
93. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
94. Cantelmo AR, Brajic A, Carmeliet P. Endothelial metabolism driving angiogenesis: emerging concepts and principles. Cancer J 2015; 21: 244-249.
95. Chamorro-Jorganes A, Lee MY, Araldi E, Landskroner-Eiger S, Fernández-Fuertes M, Sahraei M et al. VEGF-induced expression of miR-17 cluster in endothelial cells is mediated by ERK/ELK1 activation and regulates angiogenesis. Circ Res 2015; 118: 38-47.
96. Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene 2015; 34: 3107-3119.
97. Kalucka J, Missiaen R, Georgiadou M, Schoors S, Lange C, De Bock K. Metabolic control of the cell cycle. Cell cycle 2015; 14: 3379-3388.
98. Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P. The multifaceted activity of VEGF in angiogenesis-Implications for therapy responses. Cytokine Growth Factor Rev 2014; 25: 473-482.
99. Eelen G, Zeeuw P, Simons M, Carmeliet P. Endothelial cell metabolism in normal and diseased vasculature. Circ Res 2015; 116: 1231-1244.
100. Zecchin A, Stapor PC, Goveia J, Carmeliet P. Metabolic pathway compartmentalization: an underappreciated opportunity? Curr Opin Biotech 2015; 34: 73-81.
101. Beloussow K, Wang L, Wu J, Ann D, Shen W-C. Recombinant arginine deiminase as a potential anti-Angiogenic agent. Cancer Lett 2002; 183: 155-162.
102. Park I-S, Kang S-W, Shin Y-J, Chae K-Y, Park M-O, Kim M-Y et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumor growth. Br J Cancer 2003; 89: 907-914.
103. Thomas JB, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumor necrosis factor a and endotoxin. Biochem J 2002; 363: 581-587.
104. Noh EJ, Kang SW, Shin YJ, Kim DC, Park I-S, Kim MY et al. Characterization of Mycoplasma arginini deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis. Mol Cells 2002; 13: 137-143.
105. Fraisl P. Crosstalk between oxygen-And nitric oxide-dependent signaling pathways in angiogenesis. Exp Cell Res 2013; 319: 1331-1339.
106. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in tumor angiogenesis. Cancer Treat Res 2004; 117: 155-167.
107. Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res. 2001; 61: 376-382.
108. Carreau A, Kieda C, Grillon C. Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitment. Exp Cell Res 2011; 317: 29-41.
109. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534.
110. Lee MY, Luciano AK, Ackah E, Rodriguez-Vita J, Bancroft TA, Eichmann A et al. Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates. Proc Natl Acad Sci USA 2014; 111: 12865-12870.
111. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98: 2604-2609.
112. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 2005; 115: 1816-1827.
113. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 2008; 14: 255-257.
114. Roberts DD, Isenberg JS, Ridnour LA, Wink DA. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 2007; 13: 795-798.
115. McAlpine JA, Lu H-T, Wu KC, Knowles SK, Thomson JA. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer 2014; 14: 621.
116. Liu J, Ma J, Wu Z, Li W, Zhang D, Han L et al. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling. BMC Cancer 2014; 14: 686.
117. Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res 2013; 74: 896-907.
118. Daylami R, Muilenburg DJ, Virudachalam S, Bold RJ. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res 2014; 33: 102.
119. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol 1996; 114B: 107-132.
120. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336: 1-17.
121. Morris SM Jr. Regulation of enzymes of urea and arginine synthesis. Annu Rev Nutr 1992; 12: 81-101.
122. Gotoh T, Sonoki T, Nagasaki A, Tereda K, Takiguchi M, Mori M. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett 1996; 395: 119-122.
123. Elms S, Chen F, Wang Y, Qian J, Askari B, Pandey D et al. Insights into the arginine paradox: evidence against the importance of subcellular location of arginase and eNOS. Am J Physiol Heart Circ Physiol 2013; 305: H651-H666.
124. Morris SM Jr. Arginine metabolism: boundaries of our knowledge. J Nutr 2007; 137: 1602S-1609S.
125. Li H, Meininger CJ, Hawker Jr JR , Haynes TE, Kepka-Lenhart D, Mistry SK et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001; 280: E75-E82.
126. Bach SJ, Lasnitzki I. Some aspects of the role of arginine and arginase in mouse carcinoma. Enzymologia 1947; 12: 198-205.
127. Bach SJ, Maw GA. Creatine synthesis by tumor-bearing rats. Biochim Biophys Acta 1953; 11: 69-78.
128. Koji T, Terayama H. Arginase as one of the inhibitory principles in the density-dependent as well as plasma membrane-mediated inhibition of liver cell growth in vitro. Exp Cell Res 1984; 155: 359-370.
129. Terayama H, Koji T, Kontani M, Okumoto T. Arginase is an inhibitory principle in liver growth of various mammalian cells in vitro Plasma membranes arresting the growth of various mammalian cells in vitro. Biochim Biophys Acta 1982; 720: 188-192.
130. Huang M-H, Yang C-C, Wang C-C. Inhibition of lymphocyte proliferation by liver arginase. Life Sci 1992; 51: 1725-1730.
131. Cheng PNM, Lam TL, Lam WM, Tsui SM, Cheng AWM, Lo WH et al. Pegylated recombinant human arginase (rharg-peg 5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007; 67: 309-317.
132. Wheatley DN, Campbell E. Arginine deprivation, growth inhibition and tumor cell death: 3. Deficient utilisation of citrulline by malignant cells. Br J Cancer 2003; 89: 573-576.
133. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY et al. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009; 9: 9.
134. Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL et al. Replacing Mn2+ with Co2+ in human arginase I enhances cytotoxicity toward L-Arginine auxotrophic cancer cell lines. ACS Chem Biol 2010; 5: 333-342.
135. Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol 2011; 4: 138-146.
136. Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE et al. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leukemia Res 2013; 37: 1565-1571.
137. Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ. Human recombinant arginase I (Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. J Neurooncol 2015; 122: 75-85.
138. Li L, Wang Y, Chen J, Cheng B, Hu J, Zhou Y et al. An engineered arginase FC protein inhibits tumor growth in vitro and in vivo. Evid Based Complement Alternat Med 2013; 2013: 423129.
139. Lam TL, Wong GKY, Chow HY, Chong HC, Chow TL, Knok SY et al. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 2010; 24: 366-376.
140. Lam TL, Wong GKY, Chong HC, Cheng PNM, Choi SC, Chow TL et al. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 2009; 277: 91-100.
141. Yau T, Cheng PNM, Chan P, Chan W, Chen L, Yuen J et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 2013; 31: 99-107.
142. Yau CC, Chan P, Pang R, Chan W, Cheng PNM, Poon R. A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2010; 28: e13503.
143. Ferraro E, Cecconi F. Autophagic and apoptotic response to stress signals in mammalian cells. Arch Biochem Biophys 2007; 462: 210-219.
144. Jiang P, Mizushima N. Autophagy and human diseases. Cell Res 2014; 24: 69-79.
145. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891-2906.
146. Macintosh RL, Ryan KM. Autophagy in tumour cell death. Semin Cancer Biol 2013; 23: 344-351.
147. Fulda S, Köge D. Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene 2015; 34: 5105-5113.
148. Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ 2012; 19: 87-95.
149. Shen H-M, Codongo P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy 2011; 7: 457-465.
150. Efeyan A, Zoncu R, Sabatini DM. Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med 2012; 18: 524-533.
151. Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene 2013; 32: 3923-3932.
152. Yan L, Lamb RF. Amino acid sensing and regulation of mTORC1. Semin Cell Dev Biol 2012; 23: 621-625.
153. Ryter SW, Cloonan SM, Choi AMK. Autophagy: a critical regulator of cellular metabolism and homeostasis. Mol Cells 2013; 36: 7-16.
154. Cui J, Gong Z, Shen H-M. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. Biochim Biophys Acta Rev Cancer 2013; 1836: 15-26.
155. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-14494.
156. Hsueh EC, Knebel SM, Lo W-H, Leung Y-C, Cheng PNM, Hsueh CT. Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol Oncol 2012; 5: 17-22.
157. Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000; 83: 800-810.
158. Wang Y, Nartiss Y, Steipe B, McQuibban GA, Kim PK. ROS-induced mitochondrial depolarization initiates PARK2/PARKIN-dependent mitochondrial degradation by autophagy. Autophagy 2012; 8: 1462-1476.
159. Li Z-Y, Yang Y, Ming M, Liu B, Mitochondrial ROS. generation for regulation of autophagic pathways in cancer. Biochem Biophys Res Commun 2011; 414: 5-8.
160. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008; 15: 171-182.
161. Wang Z, ShiX LiY, Zeng X, Fan J, Sun Y et al. Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells. Appl Microbiol Biotechnol 2014; 98: 2485-2494.
162. Wu WKK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FKL et al. The autophagic paradox in cancer therapy. Oncogene 2012; 31: 939-953.
163. Rebsamen M, Pochini L, Stasyk T, de Araujo MEG, Galluccio M, Kandasamy RK et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 2015; 519: 477-481.
164. Wang S, Tsun Z-Y, Wolfson RL, Shen K, Wyant GA, Plovanich ME et al. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 2015; 347: 188-194.
165. Eng CH, Abraham RT. The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 2011; 30: 4687-4696.
166. Pérez E, Das G, Bergmann A, Baehrecke EH. Autophagy regulates tissue overgrowth in a context-dependent manner. Oncogene 2015; 34: 3369-3376.
167. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005; 12: 1528-1534.
168. Wang Z, Shi X, Li Y, Fan J, Zeng X, Xian Z et al. Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis 2014; 5: e1563.
169. Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cellular Signal 2014; 26: 549-555.
170. Fimia GM, Corazzari M, Antonioli M, Piacentini M. Ambra1 at the crossroad between autophagy and cell death. Oncogene 2013; 32: 3311-3318.
171. Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29: 1717-1719.
172. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C et al. Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 2010; 115: 5214-5221.
173. Morrow K, Hernandez CP, Raber P, Del Valle L, Wilk AM, Majumdar S et al. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia 2013; 27: 569-577.
174. Chow AK, Ng L, Sing LiH, Cheng CW, Lam CS, Yau TC, Cheng PN et al. Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. Curr Cancer Drug Targets 2012; 12: 1233-1243.
175. Marino T, Russo N, Toscano M. What occurs by replacing Mn2+ with Co2+ in human arginase I: first-principles computational analysis. Inorg Chem 2013; 52: 655-659.
176. Glazer ES, Kaluarachchi WD, Massey KL, Zhu C, Curley SA. Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1. Surgery 2010; 148: 310-318.
177. Regunathan S, Reis DJ. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylase. J Neurochem 2000; 74: 2201-2208.
178. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994; 263: 966-969.
179. Zhu MY, Iyo A, Piletz JE, Regunathan S. Expression of human arginine decarboxylase, the biosynthetic enzyme for agmatine. Biochim Biophys Acta 2004; 1670: 156-164.
180. Molderings GJ, Haenisch B. Agmatine (decarboxylated l-Arginine): physiological role and therapeutic potential. Pharmacol Ther 2012; 133: 351-365.
181. Dudkowska M, Lai J, Gardini G, Stachurska A, Grzelakowska-Sztabert B, Colombatto S et al. Agmatine modulates the in vivo biosynthesis and interconversion of polyamines and cell proliferation. Biochim Biophys Acta 2003; 1619: 159-166.
182. Satriano J, Matsufuji S, Murakami Y, Lortie MJ, Schwartz D, Kelly CJ et al. Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J Biol Chem 1998; 273: 15313-15316.
183. Choi YS, Cho YD. Effects of agmatine on polyamine metabolism and the growth of prostate tumor cells. J Biochem Mol Biol 1999; 32: 173-180.
184. Mayeur C, Veuillet G, Michaud M, Raul F, Blottiére H, Blachier F. Effects of agmatine accumulation in human colon carcinoma cells on polyamine metabolism, DNA synthesis and the cell cycle. Biochim Biophys Acta 2005; 1745: 111-123.
185. Moinard C, Cynober L, Bandt JPD. Polyamines: metabolism and implications in human diseases. Clin Nutr 2005; 24: 184-197.
186. Satriano J. Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines. Amino Acids 2004; 26: 321-329.
187. Philip R, Campbell E, Wheatley DN. Arginine deprivation, growth inhibition and tumor cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. Br J Cancer 2003; 88: 613-623.
188. Wheatley DN, Scott L, Lamb J, Smith S. Single amino acid (arginine) restriction: growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol Biochem 2000; 10: 37-55.
189. Wheatley DN, Campbell E. Arginine catabolism, liver extracts and cancer. Pathol Oncol Res 2002; 8: 18-25.
190. Bronte V, Zanovello P. Regulation of immune responses by L-Arginine metabolism. Nat Rev Immunol 2005; 5: 641-654.
191. Sikalidis AK. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res 2015; 21: 9-17.
192. Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-Arginine by myeloid-derived suppressor cells in cancer: Mechanisms of T-cell suppression and therapeutic perspectives. Immunol Invest 2012; 41: 614-634.
193. Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E et al. Role of arginine metabolism in immunity and immunopathology. Immunobiol 2008; 212: 795-812.
194. Popovic PJ, Zeh HJ III, Ochoa JB. Arginine and immunity. J Nutr 2007; 137: 1681s-1686s.
195. Wheatley DN, Campbell E, Lai PBS, Cheng PNM. A rational approach to the systemic treatment of cancer involving medium-term depletion of arginine. Gene Ther Mol Biol 2005; 9: 33-40.
196. Kilberg MS, Balasubramanian M, Fu L, Shan J. The transcription factor network associated with the amino acid response in mammalian cells. Adv Nutr 2012; 3: 295-306.
197. Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010; 11: 113-127.
198. Zang H, Forman HJ. Glutathione synthesis and its role in redox signaling. Semin Cell Dev Biol 2012; 23: 722-728.
199. Weiger TM, Hermann A. Cell proliferation, potassium channels, polyamines and their interactions: a mini review. Amino Acids 2014; 46: 681-688.
200. Lind D. Arginine and cancer. J Nutr 2004; 134: 2837s-2841s.
201. Kohler ES, Sankaranarayanan S, Van Ginneken CJ, Van Dijk P, Vermeulen JLM, Ruijter JM et al. The human neonatal small intestine has the potential for arginine synthesis; developmental changes in the expression of argininesynthesizing and catabolizing enzymes. BMC Dev Biol 2008; 8: 107.
202. Kim JE, Kim SY, Lee KW, Lee HJ. Arginine deiminase originating from Lactobacillus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1phase cellcycle arrest and apoptosis in SNU1 stomach adenocarcinoma cells. Br J Nutr 2003; 102: 1469-1476.
203. Gill P, Pan J. Inhibition of cell division in L5178Y cells by arginine-degrading mycoplasmas: the role of arginine deiminase. Can J Microbiol 1970; 16: 415-419.
204. Kim JH, Kim JH, Yu YS, Kim DH, Min BH, Kim KW. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep 2007; 18: 1373-1377.
205. Huang CC, Tsai ST, Kuo CC, Chang JS, Jin YT, Chang JY et al. Arginine deprivation as a new treatment strategy for head and neck cancer. Oral Oncol 2012; 48: 1227-1235.
206. Tan B, Yin Y, Kong X, Li P, Li X, Gao H et al. L-Arginine stimulates proliferation and prevents endotoxin-induced death of intestinal cells. Amino Acids 2010; 38: 1227-1235.
207. Wheatley DN, Philip R, Campbell E. Arginine deprivation and tumor cell death: arginase and its inhibition. Mol Cell Biochem 2003; 244: 177-185.
208. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004; 22: 1815-1822.
209. Feun LG, You M, Wu C, Wangpaichitr M, Kuo MT, Marini A et al. Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM) [abstract]. J Clin Oncol 2010; 28: 8528.
210. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2013; 31: 425-434.
211. Szlosarek PW, Steele J, Sheaff M, Szyszko T, Ellis S, Nolan L. A randomised phase II trial of pegylated arginine deiminase in patients with malignant pleural mesothelioma. 15th World Conference on Lung Cancer, Sydney, Australia, 2013, Abstr no. MO09.02.
212. Tomlinson BK, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T et al. Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors. J Clin Oncol (ASCO Meeting Abstracts) 2013; 31: 2569.
213. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N et al. Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus Docetaxel in patients with advanced malignant solid tumors. Clin Cancer Res 2015; 21: 2480-2486.
214. Bach SJ, Swaine D. The effect of arginase on the retardation of tumor growth. Br J Cancer 1965; 19: 379-386.
215. Currie GA. Activated macrophages kill tumor cells by releasing arginase. Nature 1978; 273: 758-759.